We are live on ! Find out more
ELAB icon

Elevai Labs
ELAB

1.69 USD
+0.11
6.96%
At close Updated Nov 10, 4:00 PM EST
Pre-market
After hours
1.78
+0.09
5.33%
1 day
6.96%
5 days
-9.63%
1 month
-44.59%
3 months
-81.63%
6 months
-91.01%
Year to date
-99.5%
1 year
-99.87%
5 years
-100%
10 years
-100%
 

About: PMGC Holdings Inc IS advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.

Employees: 34

Healthcare Biotechnology

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 0%
Neutral 100%
Negative 0%
Neutral
GlobeNewsWire
20 hours ago
PMGC Holdings Inc. Announces Strategic Share Acquisition in Australian Space Technology Company Orbit2Orbit
NEWPORT BEACH, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (“PMGC” or the “Company”), a diversified public holding company, announces that PMGC Capital LLC, the Company's investment arm, has completed a subscription for common shares in Orbit2Orbit Pty Ltd (“Orbit2Orbit”), an Australian space technology company developing in-space logistics and infrastructure.
PMGC Holdings Inc. Announces Strategic Share Acquisition in Australian Space Technology Company Orbit2Orbit
Neutral
GlobeNewsWire
5 days ago
NorthStrive Biosciences Announces Results from EL-32 Preclinical Combination Study with Semaglutide and Plans for Next Phase of Development
Study identifies preliminary lean-mass finding at the highest EL-32 dose while informing future preclinical development strategy Results advance NorthStrive Biosciences' engineered probiotic platform targeting muscle preservation for patients on GLP-1 weight loss treatments NEWPORT BEACH, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC” or the “Company”) today announced the completion of a preclinical study evaluating EL-32, an engineered probiotic candidate being developed by its wholly owned subsidiary, NorthStrive Biosciences Inc. (“NorthStrive”), both as a standalone treatment and in combination with semaglutide, the GLP-1 receptor agonist that is the active ingredient in Ozempic® and Wegovy®.
NorthStrive Biosciences Announces Results from EL-32 Preclinical Combination Study with Semaglutide and Plans for Next Phase of Development
Neutral
GlobeNewsWire
1 month ago
PMGC Holdings Inc. Announces DBA as NorthStrive Holdings, Inc., Trademark License Agreement, and Website Update
Adoption of NorthStrive® brand marks and DBA registration establishes a unified identify across PMGC's public holding company structure, with a formal legal name change expected within six months Adoption of NorthStrive® brand marks and DBA registration establishes a unified identify across PMGC's public holding company structure, with a formal legal name change expected within six months
PMGC Holdings Inc. Announces DBA as NorthStrive Holdings, Inc., Trademark License Agreement, and Website Update
Neutral
GlobeNewsWire
1 month ago
PMGC Holdings (Nasdaq: ELAB) Announces Completion of $100 Million SPAC IPO, Launching NorthStrive Acquisition Corp. I (Nasdaq: NSAI) as First in Planned SPAC Sponsorship Franchise to Expand M&A Strategy
PMGC's first sponsored SPAC adds a public-market acquisition vehicle to the holding company, targeting aerospace and defense, industrial technology, and critical supply chain manufacturers Sponsor position of approximately 2.7 million shares, or roughly 21.4% of NorthStrive Acquisition Corp I.'s Class A shares on an as-converted basis, aligns PMGC with value created through a future business combination NEWPORT BEACH, Calif.
PMGC Holdings (Nasdaq: ELAB) Announces Completion of $100 Million SPAC IPO, Launching NorthStrive Acquisition Corp. I (Nasdaq: NSAI) as First in Planned SPAC Sponsorship Franchise to Expand M&A Strategy
Neutral
GlobeNewsWire
1 month ago
NorthStrive Biosciences Partners with Charles River Laboratories to Advance Its EL-22 and EL-32 Engineered Probiotic Programs
Engagement of a leading global contract research organization strengthens the analytical foundation supporting EL-22 and EL-32 as the programs advance toward an IND-enabling development framework Builds on NorthStrive Biosciences' expanding manufacturing and characterization capabilities behind its engineered probiotic platform targeting muscle preservation, including for patients on GLP-1 weight loss treatments NEWPORT BEACH, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC” or the “Company”) today announced that its subsidiary, NorthStrive Biosciences Inc. (“NorthStrive Biosciences” or “NorthStrive”), has executed a Statement of Work (“SOW”) with Charles River Laboratories, Inc., NYSE: CRL (“Charles River” or “Charles River Laboratories”) to conduct analytical characterization supporting the development of NorthStrive Biosciences' EL-22 and EL-32 engineered probiotic programs.
NorthStrive Biosciences Partners with Charles River Laboratories to Advance Its EL-22 and EL-32 Engineered Probiotic Programs
Neutral
GlobeNewsWire
1 month ago
PMGC Holdings Inc. (Nasdaq: ELAB) Secures Five-Year Royalty Stream from Elevai Skincare Sale Under Executed Payment Agreement with Longevity Health Holdings
PMGC Holdings Inc. (Nasdaq: ELAB) Secures Five-Year Royalty Stream from Elevai Skincare Sale Under Executed Payment Agreement with Longevity Health Holdin
PMGC Holdings Inc. (Nasdaq: ELAB) Secures Five-Year Royalty Stream from Elevai Skincare Sale Under Executed Payment Agreement with Longevity Health Holdings
Neutral
GlobeNewsWire
2 months ago
NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Therapeutic Applications
NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination
NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Therapeutic Applications
Neutral
GlobeNewsWire
2 months ago
PMGC Holdings Terminates Previously Announced Acquisition LOI Following Due Diligence Review; Reaffirms Disciplined M&A Strategy and Expands Investment Across Aerospace & Defense Manufacturing Portfolio
PMGC Holdings Terminates Previously Announced Acquisition LOI Following Due Diligence Review; Reaffirms Disciplined M&A Strategy and Expands Investment Acr
PMGC Holdings Terminates Previously Announced Acquisition LOI Following Due Diligence Review; Reaffirms Disciplined M&A Strategy and Expands Investment Across Aerospace & Defense Manufacturing Portfolio
Neutral
GlobeNewsWire
2 months ago
PMGC Holdings Announces Term Sheet with Orbit2Orbit for NorthStrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin A Assets, EL-22 and EL-32, Targeting Microgravity-Induced Muscle Loss
PMGC Holdings Announces Term Sheet with Orbit2Orbit for NorthStrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin A Assets, EL-22
PMGC Holdings Announces Term Sheet with Orbit2Orbit for NorthStrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin A Assets, EL-22 and EL-32, Targeting Microgravity-Induced Muscle Loss
Neutral
GlobeNewsWire
2 months ago
NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight
NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight
NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight
See News Rankings
Price charts implemented using Lightweight Charts™